Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.
Vertex has cancelled plans to test an investigational triple combo at several sites in France.
Repeated drug price hikes have caught plenty of criticism lately, but the attention isn't dissuading everyone.
Teva may be decimating its employee ranks and struggling under a mountain of debt, but Warren Buffett apparently likes what he sees.
Mental health experts question whether allowing Johnson & Johnson to market its antipsychotic med Invega Sustenna as a way to prevent arrest is really a…
PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous…
With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.
A former chemist at Merck & Co. is facing criminal charges—and a potential sentence of up to 20 years—after allegedly stealing cyanide from a lab.
Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.
One analyst takeaway from Shire’s 2018 outlook: Consensus earnings estimates probably need to come down.